References

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

10.3322/caac.21834 · 2024 · External reference

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

10.1056/nejm199603143341104 · 1996 · External reference

Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience.

10.1002/lt.22365 · 2011 · External reference

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

10.1053/jhep.2001.24563 · 2001 · External reference

Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.

10.1097/tp.0b013e31816b67e4 · 2008 · External reference

Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.

10.1016/s1470-2045(20)30224-2 · 2020 · External reference

Downstaging outcomes for hepatocellular carcinoma: results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.

10.1053/j.gastro.2021.07.033 · 2021 · External reference

Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: a mini review.

10.1016/j.iliver.2022.10.001 · 2022 · External reference

Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy.

10.1002/hep.32613 · 2022 · External reference

Downstaging hepatocellular carcinoma: a systematic review and pooled analysis.

10.1002/lt.24169 · 2015 · External reference

AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

10.1097/hep.0000000000000466 · 2023 · External reference

Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

10.1056/evidoa2100070 · 2022 · External reference

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

10.1056/nejmoa1915745 · 2020 · External reference

Immunotherapy and transplantation for hepatocellular carcinoma.

10.1016/j.jhep.2024.01.011 · 2024 · External reference

Immune checkpoint therapy-current perspectives and future directions.

10.1016/j.cell.2023.03.006 · 2023 · External reference

Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review.

10.1111/ajt.15811 · 2020 · External reference

Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study.

10.1016/j.ajt.2024.04.007 · 2024 · External reference

Chinese expert consensus on the application of immune checkpoint inhibitors in liver transplantation for hepatocellular carcinoma.

10.1097/cm9.0000000000003237 · 2024 · External reference

Antithymocyte globulin use for corticosteroid nonresponsive rejection after liver transplantation.

10.1016/j.transproceed.2018.09.001 · 2018 · External reference

Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.

10.1016/j.jhep.2024.05.037 · 2024 · External reference

Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion?

10.21037/hbsn.2020.03.09 · 2021 · External reference

Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?

10.1016/j.jhep.2023.03.032 · 2023 · External reference

Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion—a multi-center retrospective cohort study.

10.1111/tri.13586 · 2020 · External reference

Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review.

10.3748/wjg.v21.i39.11185 · 2015 · External reference

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.

10.1016/s1470-2045(24)00457-1 · 2024 · External reference

Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma.

10.1001/jamasurg.2022.2800 · 2022 · External reference

Assessing competing risks for death following liver transplantation for hepatocellular carcinoma.

10.1007/s10620-019-05538-1 · 2019 · External reference

Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis.

10.1016/j.jhep.2024.06.042 · 2025 · External reference

Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: an international retrospective cohort study.

10.1097/hep.0000000000001289 · 2025 · External reference

Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicenter retrospective cohort study.

10.1136/gutjnl-2025-336719 · 2025 · External reference

EASL clinical practice guidelines on the management of hepatocellular carcinoma.

10.1016/j.jhep.2024.08.028 · 2025 · External reference

Sex disparities in hepatocellular carcinoma immunotherapy: hormonal and genetic influences on treatment efficacy.

10.3389/fimmu.2025.1607374 · 2025 · External reference

Sex differences in genomic features of hepatitis B–associated hepatocellular carcinoma with distinct antitumor immunity.

10.1016/j.jcmgh.2022.10.009 · 2023 · External reference

The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma.

10.3389/fonc.2024.1363695 · 2024 · External reference

Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study.

10.1097/hep.0000000000001231 · 2025 · External reference

Hepatocellular carcinoma with macrovascular invasion: need a personalized medicine for this complicated event.

10.21037/hbsn-23-653 · 2024 · External reference

Sex and size disparities in access to liver transplant for patients with hepatocellular carcinoma.

10.1001/jamasurg.2024.3498 · 2024 · External reference